BioSpace News Archive

Mallinckrodt today confirmed enrollment of the first patient in the company’s Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel as a therapy option in patients with pulmonary sarcoidosis.

Medizone today announced the appointment of Jude P. Dinges, as its Executive VP - Commercial Operations.

The investment underscores BioAgilytix’s commitment to effectively addressing customers’ evolving biomarker assay needs.

Syros announced that it has priced an underwritten public offering of 4,188,481 shares of common stock at a price to the public of $9.55 per share, before underwriting discounts and commissions, which would result in aggregate gross proceeds of approximately $40.0 million.

Sales in the first nine months of FY2017 decreased 0.6% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to ¥999.4 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

Avita Medical announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 31 December 2017.

During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.

Rare disease giant Shire plunked down an undisclosed sum to get its hands on a preclinical autoimmune drug candidate being developed by AB Biosciences.

The startup is working to develop pharmaceutical technology born out of Johns Hopkins University.

With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.